Stent Comparison: XIENCE Sierra Stent System and Other Drug-Eluting Stents

XIENCE Sierra combines a best-in-class safety profile with exemptional deliverability to address to increasingly complex patients and lesions often seen in today´s cath lab. 

When comparing drug-eluting stents, both safety and acute performance play a critical role in the outcome of the case. XIENCE Sierra raises the bar in deliverability10 and sets the standard in safety3

Click on the comparisons to learn more.

Xience Sierra Vs. Synergy

XIENCE has exceptional long-term safety rates in a variety of patient populations4, and more DAPT patients have been studied than with Synergy7.

Xience Sierra Vs. Resolute Onyx

XIENCE Sierra offers improved pushability and superior longitudinal strength for performance in challenging anatomy5.

Xience Sierra Vs. Orsiro

XIENCE has the best stent retention of any DES9 and proven safety in complex patients6.

AP2947113-WBU Rev. A

  1. Compared to XIENCE Alpine
  2. Data on file at Abbott.
  3. XIENCE showed significant benefit compared to several DES and composite BMS in multiple large scale meta-analyses and other RCTs. Source: Palmerini, et al. The Lancet. 379:9824, 14-20 April 2012, pp. 1393-1402; Bangalore S, et al. Circ Cardiovasc Interv, Aug 6, 2013. doi: 10.1161/circinterventions.113.000415; Valgimigli, Effects of Cobal-chromium Everolimus eluting or bare metal stent on fatal and non-fatal cardiovascular events. A patient-level meta analysis. EuroPCR 2014; Serruys, PW, et al. RESOLUTE All Comers Trial, NEJM 2010. Published online June 16, 2010; Fajadet, J., et al. PLATINUM PLUS 30-day Poster, TCT 2012.
  4. SPIRIT II (n=223), SPIRIT III (n=669), SPIRIT IV (n=2,458), SPIRIT V (n=1,662), SPIRIT Women (n=1,506), XIENCE V USA (n=6,516), XIENCE V India (n=931), COMPARE (n=897), STOPDAPT (n=1,525). 
  5. Data on file at Abbott.
  6. Test performed by and data on file at Abbott.
  7. SENIOR Trial (n=605), EVOLVE Short DAPT (n=2,000), IDEAL Left Main (n = 818), POEM (n=1,023).
  8. Test performed and data on file at Abbott. 3.0 x 18 mm XIENCE Sierra(TM), Orsiro(TM), and Resolute Onyx(TM) texted. 3.0 x 20 mm Synergy(TM) tested.
  9. Comparative claim refers to major drug-eluting stent manufacturers in U.S. market, as well as BIOTRONIK. Orsiro™ is not available or for sale in the United States as of November  2018.  Tests performed by and data on file at Abbott. Longitudinal data refers to 3.0 mm diameter and 28-30 mm lengths. 
  10. Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?
Important safety information